Inhibitors in previously treated patients: A review of the literature

Haemophilia

Volumn 16, Issue 102, 2010, Pages 61-65

  Kempton, C L ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Haemophilia; Inhibitor; Previously treated patients; PTP

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; EPITOPE; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGENICITY; ARTICLE; AUTOIMMUNITY; BLEEDING; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG EXPOSURE; DRUG SURVEILLANCE PROGRAM; GEOGRAPHIC DISTRIBUTION; HEMOPHILIA A; HUMAN; INCIDENCE; LONG TERM CARE; POPULATION RESEARCH; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

BLOOD COAGULATION FACTOR INHIBITORS; COHORT STUDIES; FACTOR VIII; HEMOPHILIA A; HUMANS; POPULATION SURVEILLANCE; RISK FACTORS;

EID: 77953225901     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02235.x     Document Type: Article

References (22)

1. White GC, DiMichele D, Mertens K. Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1999, 81:462.
2. Peerlinck K, Arnout J, Gilles JG, Saint-Remy JM, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993, 69:115-18.
3. Rosendaal FR, Nieuwenhuis HK, van den Berg HM. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands. Dutch Hemophilia Study Group. Blood 1993, 81:2180-6.
4. Peerlinck K, Arnout J, Di Giambattista M. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 1997, 77:80-6.
5. Giles AR, Rivard GE, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci 1998, 19:139-48.
6. Rubinger M, Lillicrap D, Rivard GE. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose. Haemophilia 2008, 14:281-6.
7. Ewenstein BM, Gomperts ED, Pearson S, O'Banion ME. Inhibitor development in patients receiving recombinant factor VIII (Recombinate rAHF/Bioclate): a prospective pharmacovigilance study. Haemophilia 2004, 10:491-8.
8. Aygoren-Pursun E, Scharrer I. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. German Kogenate Study Group. Thromb Haemost 1997, 78:1352-6.
9. Gringeri A, Tagliaferri A, Tagariello G, Morfini M, Santagostino E, Mannucci P. Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII. Br J Haematol 2004, 126:398-404.
10. Roussel-Robert V, Torchet MF, Legrand F, Rothschild C, Stieltjes N. Factor VIII inhibitors development following introduction of B-domain-deleted recombinant factor VIII in four hemophilia A previously treated patients. J Thromb Haemost 2003, 1:2450-1.
11. Gomperts ED. Advate inhibitor risk profile: 18 months post-licensure. 35th Hemophilia Symposium 2004 2006, 38-41. Scharrer IWolfgang S. In, eds, Hamburg, Springer-Verlag
12. McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988, 71:344-8.
13. Ehrenforth S, Kreuz W, Scharrer I. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992, 339:594-8.
14. Darby SC, Keeling DM, Spooner RJ. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004, 2:1047-54.
15. Kempton CL, Soucie JM, Abshire TC. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. J Thromb Haemost 2006, 4:2576-81.
16. Schwartz RS, Abildgaard CF, Aledort LM. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. Recombinant Factor VIII Study Group. N Engl J Med 1990, 323:1800-5.
17. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. Semin Hematol 2001, 38:44-51.
18. Tarantino MD, Collins PW, Hay CR. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004, 10:428-37.
19. von Auer C, Oldenburg J, Krause M, Meisbach W, Scharrer I. Inhibitors in PTP's: a retrospective study in Germany. 35th Hemophilia Symposium 2004 2006, 201-4. Scharrer I, Wolfgang S, In, eds, Hamburg, Springer-Verlag
20. von Auer C, Oldenburg J, von Depka M. Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates. Ann N Y Acad Sci 2005, 1051:498-505.
21. White GC, Courter S, Bray GL, Lee M, Gomperts ED. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group. Thromb Haemost 1997, 77:660-7.
22. Abshire TC, Brackmann HH, Scharrer I. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy - International Kogenate-FS Study Group. Thromb Haemost 2000, 83:811-6.